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Introduction 
This document presents our list of  adult diseases related to smoking and the corresponding relative 
risks of disease due to smoking, explaining our choices of disease definitions and risk sources. Figure 1 
shows the variation in disease-specific risks. We focus on the risks of current smoking and limit 
ourselves to diseases that affect the consumer themselves e.g. excluding secondary effects of smoking 
on children. We assume the equivalence of relative risks and odds ratios. Our starting point was the 
ZŽǇĂůŽůůĞŐĞŽĨWŚǇƐŝĐŝĂŶ ?Ɛ  ?ZW ?ƌĞƉŽƌƚ  “,ŝĚŝŶŐ ŝƉůĂŝŶƐŝŐŚƚ PdƌĞĂƚŝŶŐƚŽďĂĐĐŽĚĞƉĞŶĚĞŶĐǇ ŝŶ ƚŚĞ
E,^ ?[1], which reviewed smoking Wdisease associations to produce an updated list of diseases that are 
caused by smoking and updated risk sources. We mainly ŬĞĞƉƚŽƚŚĞZWƌĞƉŽƌƚ ?ƐĚŝƐĞĂƐĞůŝƐƚ, with any 
deviations from the RCP list and risk sources being for one of two reasons:  
1) There are often slightly conflicting ICD-10 code definitions used for some conditions and we have 
sought to harmonise these consistently across both tobacco and alcohol, based on the Sheffield 
Alcohol Policy Model (SAPM) v4.0 disease list [2];  
2) Since publication of the RCP report, Cancer Research UK (CRUK) produced their own disease list 
and risk sources for cancers attributable to modifiable risk factors, including tobacco and alcohol 
[3]. Discussions with CRUK shaped the disease definitions in our updated Sheffield disease list for 
alcohol. Where there are differences in the risk sources used in the RCP repŽƌƚĂŶĚZh< ?ƐǁŽƌŬ ?
we take the estimate that matches most closely to our disease definitions, or the more recent 
estimate. 
 
Tobacco WAlcohol interactions in disease risk 
There is limited evidence for the risk of disease in someone who consumes both tobacco and alcohol 
(RRta) being higher than would be expected from combining the independent risks from tobacco (RRt) 
and alcohol (RRa). This additional risk due to tobacco-alcohol interaction (over and above the 
combination of the independent contributions to risk from tobacco and alcohol) can be expressed as a 
 ‘ƐǇŶĞƌŐǇĨĂĐƚŽƌ ?(1) [4, 5].  
 ܵܨ ൌ ோோ೟ೌሺோோ೟ିଵሻାሺோோೌିଵሻ          (1) 
 
We conducted a scoping review across all diseases for which tobacco and alcohol are causal factors to 
ascertain the extent of evidence on interaction effects. We include only interactions with a meta-
analysis of effect size. The only diseases for which we have found suitable meta-analyses to inform the 
tobacco Walcohol interaction in risk are cancers of the oral cavity, pharynx, larynx and oesophagus. To 
evaluate the interaction between tobacco and alcohol and the risk of cancer of the oral cavity, pharynx 
and larynx, Hashibe et al. [5] conducted a pooled analysis within the INHANCE consortium. For the oral 
cavity and pharynx, the SF was estimated to be 3.09 (CI 1.82 W5.23) i.e. smoking and drinking together 
causes around a 3-fold increase in the risk of head and neck cancers over and about the independent 
contributions of tobacco and alcohol. For cancer of the larynx, Hashibe et al.[5] estimate the SF to be 
1.62 (CI 0.85 W3.09). For cancer of the oesophagus, Prabhu et al. [4] estimated the increase in risk of 
Squamous Cell Carcinoma in people who both smoke and drink to be characterised by a synergy factor 
of 1.85 (CI 1.45 W2.38).  
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Figure 1. Relative risks and 95% confidence intervals in current smokers for 52 conditions attributable 
to smoking. 
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Cancers 
We include all cancers attributable to tobacco as mentioned by CRUK [3], except ovarian cancer. 
Smoking only carries a risk for fully malignant mucinous ovarian cancers (13% of ovarian cancers are 
mucinous, and of these 57% are fully malignant). We excluded ovarian cancer due to the uncertainty 
involved in identifying the cases attributable to smoking based on the ICD-10 definitions used in our 
mortality data and hospital episode statistics. 
 
Below we itemise each cancer type and explain how we have synthesised the definitions of cancers and 
the sources for the relative risk of smoking among the Sheffield alcohol disease list [2], RCP report [1], 
ĂŶĚZh< ?ƐƉĂƉĞƌ[3]. 
 
Oral cavity (C00 WC06), and pharyngeal (C09, C10, C12 WC14) 
Gandini et al. [6] estimated the relative risk of smoking for cancer in the oral cavity as 3.43 (95% 
Confidence Interval 2.37 W4.94), and pharyngeal cancers as 6.76 (CI 2.86 W16.0). Following Gandini, the 
RCP report associated the relative risk from Gandini for oral cavity (RR 3.43) with ICD10 code C10, and 
relative risk for pharyngeal cancer (RR 6.76) with ICD10 code C14. But in line with CRUK, we instead use 
the risk that Gandini associated with oral cavity cancer (RR 3.43) for pharyngeal cancers with ICD10 
codes C09, C10, C12 WC14. For oral cavity, we use the risk from Maasland et al. [7] of 1.91 (CI 1.06 W3.42) 
with ICD10 codes C00 WC06. 
 
Oesophageal (C15) 
Gandini et al. [6] estimated the relative risks of smoking for cancer of the oesophagus as 2.50 (CI 2.00 W
3.13). Differing from the RCP report but in-line with CRUK, we split oesophageal cancer into its two 
main histological types: Squamous Cell Carcinoma (SCC) and Adenocarcinoma (AC). CRUK use different 
relative risks of smoking for each subtype: following CRUK, for SCC, we use the risk from Prabhu et al. 
[8] of 4.21 (CI 3.13 W5.66); for AC, we use the risk from Tramacere et al. [9] of 2.32 (CI 1.96 W2.75). We 
apportion overall oesophageal cancer prevalence between AC and SCC using data on percentage 
prevalence by age and sex from cancer registries, supplied to us by CRUK. 
 
Colorectal (C18 WC20) 
The RCP report used the CHANCES consortium [10] estimate of the relative risk of smoking for 
colorectal cancer of 1.20 (CI 1.07 W1.34). CRUK instead use the estimates of Cheng et al. [11], who 
produce two separate risks of smoking for cancer of the colon and rectum (RR 1.11, 1.44). To align with 
the SAPM disease list, we define colorectal cancer as a single disease and use the CHANCES risk estimate 
in-line with the RCP report. 
 
Liver (C22) 
The RCP report used Lee et al. ?Ɛ [12] estimate of the risk of smoking for liver cancer of 1.51 (CI 1.37 W
1.67). CRUK use the same source but take the sex-specific effects: 1.61 (CI 1.38 W1.89) for males and 
1.86 (CI 1.33 W2.60) for females. Due to the substantial overlap between the sex-specific confidence 
intervals, we use the overall estimate. 
 
Pancreatic (C25) 
CRUK ƵƐĞĚŽƐĞƚƚŝĞƚĂů ? ?Ɛ[13] estimate from the PanC4 study that the risk of smoking for pancreatic 
cancer is 2.20 (CI 1.71 W2.83). The RCP report used the CHANCES consortium [10] estimate of 1.90 (CI 
1.48 W2.43), and we use this more recent estimate. 
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Laryngeal (C32) 
The RCP report used Gandini et al. ?Ɛ [6] estimate for the relative risks of smoking for cancer of the larynx 
of 6.98 (CI 3.14 W15.52). CRUK used the more recent estimate by Zuo et al. [14] of 7.01 (CI 5.56 W8.85). 
We use the estimate of Zuo. 
 
Stomach (C16) 
CRUK used the estimate of Ladeiras-Lopes et al. [15] that put the relative risk of stomach cancer among 
smokers at 1.62 (CI 1.50 W1.75) for males and 1.20 (CI 1.01 W1.43) for females. The RCP report used the 
CHANCES consortium [10] estimate of 1.74 (CI 1.50 W2.02), and estimates from Gandini et al. [6] are 
similar. We use the CHANCES estimate. 
 
Lung (C33 WC34) 
CRUK used Gandini et al. ?Ɛ [6] estimate of the relative risk of lung cancer among smokers of 8.96 (CI 
6.73 W12.11). The RCP report used the more recent 2016 meta-analysis by Jayes et al. [16] estimates 
the risk to be 10.92 (CI 8.28 W14.40). We use the Jayes estimate.  
 
Cervical (C53) 
Both CRUK and the RCP report use Gandini et al. ?Ɛ [6] estimate of the relative risk of cervix cancer 
among smokers of 1.83 (CI 1.51 W2.21). 
 
Kidney (C64) 
The RCP report used Gandini et al. ?Ɛ [6] estimate of the relative risk of kidney cancer among smokers 
of 1.52 (CI 1.33 W1.74). CRUK use the more recent meta-analysis by Cumberbatch et al. [17] of 1.35 (CI 
1.13 W1.60) but associate this with ICD10 codes C64 WC66, C68. We use the Cumberbatch estimate for 
C64. 
 
Lower urinary tract (C65 WC66) 
In-line with the RCP report, we use Gandini et al. ?Ɛ [6] estimate of the relative risk of lower urinary tract 
(renal pelvis, bladder and ureter) cancer of 2.77 (CI 2.17 W3.54). 
  
 
Bladder (C67) 
The RCP report used the estimate by van Osch et al. [18] for the risk of bladder cancer among smokers 
of 3.14 (CI 2.53 W3.75). CRUK used the same source but took the sex-specific estimates of 3.44 (CI 2.67 W
4.22) for males, and 3.56 (CI 2.76 W4.36) for females. We use the overall estimate. 
 
Acute myeloid leukaemia (C92) 
CRUK used Fircanis et al. ?Ɛ [19] estimate of the relative risk of acute myeloid leukaemia among smokers 
of 1.47 (CI 1.08 W1.98) but associate it with ICD10 codes C90 WC95. The RCP report used the more recent 
meta-analysis by Colamesta et al. [20], which produced a similar estimate of 1.36 (CI 1.11 W1.66). In-line 
with the RCP report, we use the Colamesta estimate and associate it with ICD10 code C92. 
 
Nasal-sinuses and nasopharynx (C11, C30 WC31) 
The RCP report and CRUK both used Gandini et al. ?Ɛ [6] estimate of the relative risk of smoking for 
nasopharyngeal (C11) and sino-nasal (C30, C31) cancers of 1.95 (CI 1.31 W2.91). 
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Table 1. Relative risks for current vs. never smoking for 16 cancer types. 
Grouping Cancer ICD10 code Relative risk Reference 
Lung Lung C33 WC34 10.92 (8.28 W
14.40) 
Jayes et al (2016) [16] 
Head and neck Nasal sinus and 
nasopharyngeal 
C11, C30 WC31 1.95 (1.31 W2.91)  Gandini et al (2008) [6] 
Head and neck Oral cavity  C00 WC06 1.91 (1.06 W3.42) Maasland et al.(2014) 
[7] 
Head and neck Pharyngeal C09, C10, C12 W
C14 
3.43 (2.37 W4.94) Gandini et al (2008) [6] 
Head and neck Laryngeal C32 7.01 (5.56 W8.85) Zuo et al. (2017) [14] 
Gastrointestinal Oesophageal SCC C15* 4.21 (3.13 W5.66) Prabhu et al. (2013) [8] 
Gastrointestinal Oesophageal AC C15* 2.32 (1.96 W2.75) Tramacere et al. (2011) 
[9] 
Gastrointestinal Stomach C16 1.74 (1.50 W2.02)  Ordóñez-Mena et al 
(2016) [10] 
Gastrointestinal Pancreatic C25 1.90 (1.48 W2.43)  Ordóñez-Mena et al 
(2016) [10] 
Gastrointestinal Liver C22 1.51 (1.37 W1.67) Lee et al (2009) [12] 
Gastrointestinal Colorectal C18 WC20 1.20 (1.07 W1.34)  Ordóñez-Mena et al. 
(2016)  
Urinary system 
 
Kidney C64 1.35 (1.13 W1.60) Cumberbatch et al. 
(2016) [17] 
Urinary system 
 
Lower urinary tract C65 WC66 2.77 (2.17 W3.54)  Gandini et al (2008) [6] 
Urinary system 
 
Bladder C67 3.14 (2.53 W3.75) van Osch et al (2016) 
[18] 
Cervical Cervical C53 1.83 (1.51 W2.21) Gandini et al (2008) [6] 
Blood and bone 
marrow 
Acute Myeloid 
Leukaemia 
C92 1.36 (1.11 W1.66) Colamesta et al (2016) 
[20] 
* we split total oesophageal cancer into two subtype using ratios provided by CRUK 
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Cardiovascular conditions 
Our cardiovascular disease list and risk sources are all in-line with the RCP report, which discusses the 
sources available. To align with the Sheffield alcohol disease list, we split stroke into haemorrhagic (I60 W
I62) and ischaemic (I63 WI67) but use the same smoking risk for each. 
 
Table 2. Relative risks for current vs. never smoking for 6 cardiovascular conditions. 
Disease ICD10 code Relative risk Reference 
Ischaemic heart disease I20 WI25 Male 35 W64:   
3.18 (2.34 W4.33) 
Male 65+:   
1.96 (1.62 W2.37) 
Female 35 W64:   
3.93 (2.56 W6.05) 
Female 65+:  
1.95 (1.60 W2.37) 
Rostron (2013) [21] 
Haemorrhagic stroke I60 WI62 Male: 1.57 (1.49 W1.88)  
Female: 1.83 (1.58 W2.12) 
Peters et al (2013) [22] 
Ischaemic stroke I63 WI67 Male: 1.57 (1.49 W1.88)  
Female: 1.83 (1.58 W2.12) 
Peters et al (2013) [22] 
Peripheral arterial disease I73.9 2.71 (2.28 W3.21) Lu et al (2014) [23] 
Abdominal aortic aneurysm I71 2.41 (1.94 W3.01) Cornuz et al (2004) [24] 
Venous thromboembolism I26, I80 WI82 1.23 (1.14 W1.33) Cheng et al (2013) [25] 
 
Respiratory conditions 
Our respiratory disease list and risk sources are all in-line with the RCP report. We expand the definition 
ŽĨ ‘>ŽǁĞƌƌĞƐƉŝƌĂƚŽƌǇƚƌĂĐƚŝŶĨĞĐƚŝŽŶƐ ? ?: ? ?-J18) from the Sheffield alcohol disease list to accommodate 
the different risks of smoking that the RCP report identified for pneumonia (J12-J18), Influenza  W 
clinically diagnosed (J11), and Influenza  W microbiologically confirmed (J09, J10). 
 
Table 3. Relative risks for current vs. never smoking for 8 respiratory conditions. 
Grouping Disease ICD10 
code 
Relative risk Reference 
Chronic Obstructive 
Pulmonary Disease (COPD) 
Chronic Obstructive 
Pulmonary Disease (COPD) 
J40 W44, 
J47 
4.01 (3.18 W5.05) Jayes et al 
(2016) [16] 
Asthma Asthma J45 WJ46 1.61 (1.07 W2.42) Jayes et al 
(2016) [16] 
Tuberculosis Tuberculosis A15 WA19 1.57 (1.18 W2.10)  Jayes et al 
(2016) [16] 
Lower respiratory tract 
infections 
Pneumonia  J12 WJ18 2.18 (1.69 W2.80) RCP report 
(2018) [1] 
Lower respiratory tract 
infections 
Influenza  W clinically 
diagnosed 
J11 1.34 (1.13 W1.59) RCP report 
(2018) [1] 
Lower respiratory tract 
infections 
Influenza  W 
microbiologically confirmed 
J09, J10 5.69 (2.79 W11.60) RCP report 
(2018) [1] 
Idiopathic Pulmonary 
fibrosis 
Idiopathic Pulmonary 
fibrosis 
J84.1 1.58 (1.27 W1.97) Taskar et al 
(2006) [26] 
Obstructive sleep apnoea Obstructive sleep apnoea G47.3 1.97 (1.02 W3.82) Jayes et al 
(2016) [16] 
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Mental health  
Our mental health disease list and risk sources are all in-line with the RCP report. 
 
Table 4. Relative risks for current vs. never smoking for 7 mental health conditions. 
Disease ICD10 code Relative risk Reference 
ůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ G30 1.40 (1.13 W1.73) Zhong et al (2015) [27] 
Vascular dementia F01 1.38 (1.15 W1.66)  Zhong et al (2015) [27] 
All-cause dementia F02, F03 1.30 (1.18 W1.45) Zhong et al (2015) [27] 
Depression F32, F33 1.62 (1.10 W2.40)  Luger et al (2014) [28] 
Psychosis F28, F29 2.18 (1.23 W3.85)  Gurillo et al (2015) [29] 
Schizophrenia F20 WF25 2.24 (1.10 W4.55) RCP report (2018) [1] 
Bulimia F50.2 2.32 (1.12 W4.78) Solmi et al (2016) [30] 
 
Other adult diseases  
We include 13 further diseases in-line with the RCP report. 
 
Table 5. Relative risks for current vs. never smoking for 13 other adult diseases. 
Disease ICD10 code Relative risk Reference 
Rheumatoid arthritis  M05 WM06 2.02 (1.75 W2.33) Di Giuseppe et al (2014) 
[31] 
Chronic Kidney Disease N18 (excluding N18.5) 1.34 (1.23 W1.47)  Xia et al (2017) [32] 
End-stage renal disease N18.5 1.91 (1.39 W2.64)  Xia et al (2017) [32] 
Systemic Lupus 
Erythematosis 
M32 1.56 (1.26 W1.95) Jiang et al (2015) [33] 
Diabetes (type 2) E11 1.37 (1.33 W1.42)  Pan et al (2015) [34] 
Psoriasis  L40 1.78 (1.52 W2.06) Armstrong et al (2014) [35] 
Multiple sclerosis G35 1.55 (1.48 W1.62) Zhang et al (2015) [36] 
Senile cataract H25 1.47 (1.36 W1.59)  Ye et al (2012) [37] 
Age-related macular 
degeneration  
H35.3 WH52.4 1.86 (1.27 W2.73)  Chakravarthy et al (2010) 
[38] 
Low back pain M54   1.16 (1.02 W1.32) Shiri et al (2010) [39] 
ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ K50 1.76 (1.40 W2.22) Mahid et al (2006) [40] 
Hip fracture in women  S72.0 WS72.2 1.30 (1.16 W1.45)  Shen et al (2015) [41] 
Hearing loss H90, H91 1.97 (1.44 W2.70) Nomura et al. (2005) [42] 
 
Conditions less common among smokers 
We include 2 diseases in-line with the RCP report. 
 
Table 6. Relative risks for current vs. never smoking for 2 conditions less common among smokers. 
Disease ICD10 code Relative risk Reference 
Ulcerative colitis  K51 0.55 (0.33 W0.91) Dias et al (2015) [43] 
WĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ G20 0.46 (0.42 W0.51)  Breckenridge et al (2016) 
[44] 
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Decline in risk over time after quitting smoking 
To estimate the risk of disease for former smokers we used the findings of Kontis et al. [45], who re-
analysed the change in risk after smoking in the ACS-CPS II study from Oza et al.[46], producing three 
functions to describe the decline in risk after quitting for each of cancers, CVD and COPD (Figure 2). The 
estimates were informed by data on former smokers with known quit dates who were disease-free at 
baseline. The results show the proportion of excess relative risk remaining at each time-point since 
cessation. A cross-check showed that the figures for cancers were broadly consistent with the findings 
ŽĨ ƚŚĞ /ŶƚĞƌŶĂƚŝŽŶĂůŐĞŶĐǇĨŽƌZĞƐĞĂƌĐŚŽŶĂŶĐĞƌ ?Ɛ  ?/Z ?  ? ? ? ?ƌĞǀŝĞǁŽĨ ƚŚĞĚĞĐůŝŶĞ ŝŶ ƌŝsk after 
quitting smoking [47].  
 
The remaining question is how risk declines after quitting smoking for diseases that are not cancers, 
CVD or COPD. Kontis et al. [45] ƐƚĂƚĞƚŚĂƚ “Randomised trials also indicate that the benefits of behaviour 
change and pharmacological treatment on diabetes risk occur within a few years, more similar to the 
CVDs than cancers.[48] Therefore, we used the CVD curve for diabetes. ?/Ŷ-line with Kontis, we apply 
the rate of decline in risk of CVD after quitting smoking to type 2 diabetes. For other diseases, we 
assume that the relative risk reverts to 1 immediately after quitting i.e. an immediate rather than a 
gradual decline in risk. 
  
Figure 2. The proportion of remaining risk after quitting. Data from a re-analysis of ACS-CPS II data [45, 
46]. 
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